Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Uterine Cervical Neoplasms 1Neurotoxicity Syndromes 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, B-Cell 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Gliosarcoma 1Glioma 1Glioblastoma 1Cytokine Release Syndrome 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

Temozolomide 93Radiotherapy 66Bevacizumab 35Radiation 22Carmustine 21Erlotinib Hydrochloride 17Chemotherapy, Adjuvant 17Irinotecan 16Magnetic Resonance Spectroscopy 13Radiotherapy, Conformal 11O(6)-benzylguanine 11Surgical Procedures, Operative 10Radiotherapy, Intensity-Modulated 10sargramostim 9Sirolimus 9Imatinib Mesylate 9Carboplatin 9temsirolimus 8motexafin gadolinium 7Thalidomide 7Gene Expression Profiling 7aldesleukin 6Sorafenib 6Radiosurgery 6Immunohistochemistry 6Hydroxyurea 6Gefitinib 6Filgrastim 6Everolimus 6Etoposide 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Gliosarcoma × Contrast Media × Clear all
NCT04396860 2026-04-22

Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma

National Cancer Institute (NCI)

Phase 2/3 Completed
159 enrolled 17 charts
Sarcoma

Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡